Printer Friendly

CAMBRIDGE NEUROSCIENCE RECEIVES U.S. PATENTS ON CERESTAT AND RELATED NEUROPROTECTIVE COMPOUNDS

 CAMBRIDGE, Mass., Nov. 22 /PRNewswire/ -- Cambridge NeuroScience, Inc. (NASDAQ: CNSI) today announced that the U.S. Patent and Trademark Office has awarded one patent and allowed two additional patents for Cerestat(TM), the company's lead neuroprotective compound. Cerestat is currently in human clinical trials for the treatment of stroke and traumatic brain injury (TBI).
 The issued patent (U.S. Patent No. 5,262,568) covers the composition of matter of Cerestat, as well as other chemical structures numbering over 100 different compounds. The first of the two allowed patents covers methods of use to treat diseases of the nervous system, such as stroke and TBI, for all of these compounds. The second allowed patent covers the manufacturing process for Cerestat and related compounds.
 "With this broad-based patent portfolio, we have successfully protected a major segment of the company's product pipeline," said Alan J. Dalby, chairman and chief executive officer. "We therefore have a strong proprietary position with these products as we advance through clinical development toward commercialization."
 Studies of Cerestat in human volunteers were completed in the United Kingdom last year. Multi-center Phase Ib clinical studies of Cerestat are currently in progress in both the United States and United Kingdom. To date, Cerestat has been well tolerated in both stroke and traumatic brain injury patients at dosing levels believed to be clinically effective. Broad Phase II efficacy studies for stroke and TBI are scheduled to begin in 1994.
 Cambridge NeuroScience is a leading neuroscience company engaged in the discovery and development of proprietary pharmaceuticals with a focus on nerve cell survival. The company is developing a number of products to treat stroke, traumatic brain injury, schizophrenia and chronic neurodegenerative disorders, such as diabetic peripheral neuropathy and multiple sclerosis.
 -0- 11/22/93
 /CONTACT: Philip V. Holberton, chief financial officer of Cambridge NeuroScience, 617-225-0600; or Marcia A. Kean, executive VP of Feinstein Partners, 617-577-8110, for Cambridge NeuroScience/
 (CNSI)


CO: Cambrige NeuroScience, Inc. ST: Massachusetts IN: MTC SU:

CM-JL -- NE009 -- 6764 11/22/93 10:42 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 22, 1993
Words:335
Previous Article:APC CHOSEN TOP POWER PROTECTION VENDOR BY COMPUTER RESELLERS
Next Article:CACI INCREASES PRICE FOR SELF-TENDER AND RESOLVES BOARD ISSUES IN SETTLING LAWSUITS
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters